Delayed low-dose oral administration of 4′-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease

Development of broad-spectrum antiviral therapies is critical for outbreak and pandemic preparedness against emerging and reemerging viruses. Viruses inducing hemorrhagic fevers cause high morbidity and mortality in humans and are associated with several recent international outbreaks, but approved therapies for treating most of these pathogens are lacking. Here, we show that 4'-fluorouridine (4'-FlU; EIDD-2749), an orally available ribonucleoside analog, has antiviral activity against multiple hemorrhagic fever viruses in cell culture, including Nipah virus, Crimean-Congo hemorrhagic fever virus, orthohantaviruses, and arenaviruses. We performed preclinical in vivo evaluation of oral 4'-FlU against two arenaviruses, Old World Lassa virus (LASV) and New World Junín virus (JUNV), in guinea pig models of lethal disease. 4'-FlU demonstrated both advantageous pharmacokinetic characteristics and high efficacy in both of these lethal disease guinea pig models. Additional experiments supported protection of the infected animals even when 4'-FlU delivery was reduced to a low dose of 0.5 milligram per kilogram. To demonstrate clinical utility, 4'-FlU treatment was evaluated when initiated late in the course of infection (12 or 9 days after infection for LASV and JUNV, respectively). Delayed treatment resulted in rapid resolution of clinical signs, demonstrating an extended window for therapeutic intervention. These data support the use of 4'-FlU as a potent and efficacious treatment against highly pathogenic arenaviruses of public health concern with a virus inhibition profile suggesting broad-spectrum utility as an orally available antiviral drug against a wide variety of viral pathogens.

Authors

Institutions

Publication Details

Journal
Science Translational Medicine
Published
2024-11-20
DOI
https://doi.org/10.1126/scitranslmed.ado7034
Citations
20
Primary Topic
Viral Infections and Outbreaks Research
Type
article
Field-Weighted Citation Impact
7.78

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Delayed low-dose oral administration of 4′-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease

Jonna B. Westover, Jessica R. Spengler, Sarah C. Genzer, Stephen R. Welch et al.
20 citations
Science Translational Medicine
Viral Infections and Outbreaks Research
7.78
article

Delayed low-dose oral administration of 4′-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease

Jonna B. Westover, Jessica R. Spengler, Sarah C. Genzer, Stephen R. Welch, César G. Albariño, Rebecca E. Krueger, Katherine Davies, Florine E. M. Scholte, Michael Hager, George R. Painter, JoAnn D. Coleman-McCray, Punya Shrivastava-Ranjan, Christina F. Spiropoulou, Michael K. Lo, Shuli Mao, Damien L. Kuiper, Jamie A. Kelly, Kevin W. Bailey, Mike Flint, Meghan K. Andrews, Zachary M. Sticher, Laura K. McMullan, Gregory R. Bluemling, Alexander A. Kolykhalov, Manohar Saindane, Payel Chatterjee, Kirsten M. Boardman, Brian B. Gowen, Michael G. Natchus, Joel M. Montgomery, M. Harley Jenks, Teresa E. Sorvillo, Samantha R. Wasson, Kie Hoon Jung, Virginia Aida-Ficken
article en
20 citations

Abstract

Development of broad-spectrum antiviral therapies is critical for outbreak and pandemic preparedness against emerging and reemerging viruses. Viruses inducing hemorrhagic fevers cause high morbidity and mortality in humans and are associated with several recent international outbreaks, but approved therapies for treating most of these pathogens are lacking. Here, we show that 4'-fluorouridine (4'-FlU; EIDD-2749), an orally available ribonucleoside analog, has antiviral activity against multiple hemorrhagic fever viruses in cell culture, including Nipah virus, Crimean-Congo hemorrhagic fever virus, orthohantaviruses, and arenaviruses. We performed preclinical in vivo evaluation of oral 4'-FlU against two arenaviruses, Old World Lassa virus (LASV) and New World Junín virus (JUNV), in guinea pig models of lethal disease. 4'-FlU demonstrated both advantageous pharmacokinetic characteristics and high efficacy in both of these lethal disease guinea pig models. Additional experiments supported protection of the infected animals even when 4'-FlU delivery was reduced to a low dose of 0.5 milligram per kilogram. To demonstrate clinical utility, 4'-FlU treatment was evaluated when initiated late in the course of infection (12 or 9 days after infection for LASV and JUNV, respectively). Delayed treatment resulted in rapid resolution of clinical signs, demonstrating an extended window for therapeutic intervention. These data support the use of 4'-FlU as a potent and efficacious treatment against highly pathogenic arenaviruses of public health concern with a virus inhibition profile suggesting broad-spectrum utility as an orally available antiviral drug against a wide variety of viral pathogens.

Science Translational MedicineVol. 16(774)
Utah State University (US), Emory University (US), National Center for Emerging and Zoonotic Infectious Diseases (US), Auburn University (US)
U.S. Department of Energy, U.S. Department of Agriculture, Oak Ridge Associated Universities, Auburn University, National Institutes of Health, Centers for Disease Control and Prevention, Defense Threat Reduction Agency, Oak Ridge Institute for Science and Education, Agricultural Research Service, Animal and Plant Health Inspection Service, National Institute of Allergy and Infectious Diseases
Good health and well-being
Openalex Percentile: Top 2%
Viral Infections and Outbreaks Research
7.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.